Semper Paratus, Tevogen announce effectiveness of registration statement

Tevogen Bio and Semper Paratus Acquisition Corporation announced that the Securities and Exchange Commission has declared effective the registration statement on Form S-4 filed by Semper Paratus in connection with Tevogen Bio and Semper Paratus’s previously announced proposed business combination. Semper Paratus will hold an extraordinary general meeting of its stockholders at which shareholders will be asked to consider and vote upon proposals to approve the Business Combination and related matters. The Business Combination is expected to close shortly after the Special Meeting, subject to shareholder approvals and the satisfaction or waiver of the conditions in the business combination agreement and other customary closing conditions. Upon closing of the Business Combination, the post-closing combined company will be renamed Tevogen Bio Holdings Inc. Tevogen Bio and Semper Paratus previously announced, on June 29, 2023, their execution of a definitive business combination agreement. The pro forma equity value of the portion of the combined company attributable to Tevogen stockholders is an expected $1.2 billion.